Abbott India Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Excellent return on equity (ROE 34.5%)
- ✓Attractively valued vs sector (P/E 36x vs industry 54.4x)
- ✓Virtually debt-free
- ✓Regular dividends — yield 2%
Concerns
- ✗High premium to book value (P/B 11.7x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ABBOTINDIA · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 74.99% | 74.99% | 74.99% | 74.99% | 74.99% | 74.99% |
| FII | 0.18% | 0.18% | 0.18% | 0.17% | 0.17% | 0.16% |
| DII | 8.73% | 8.91% | 8.81% | 9.00% | 9.01% | 8.91% |
| Public | 16.09% | 15.92% | 16.01% | 15.86% | 15.85% | 15.94% |
Corporate Events
Dividend - Rs 525 Per Share & Special Dividend Rs 131 Per Share
Dividend - Rs 475 Per Share
Dividend - Rs 410 Per Share
Dividend - Rs 180 Per Share/ Special Dividend Rs 145 Per Share
Latest News
All news →Abbott India faces bearish momentum on technical downgrade
*Abbott India faces bearish momentum on technical downgrade* according to Markets Mojo. The stock shows weakening price action with key indicators signaling downside risk. Traders should watch support at **₹24,800** with rising volume trends suggesting further correction. \n📊 *STOCKS:* ABBOTINDIA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #technical
Abbott India downgraded on weak growth outlook
*Abbott India downgraded on weak growth outlook* — A broker has cut its rating and price target on Abbott India due to sluggish volume growth and margin pressures. The revised outlook reflects concerns over **<5% volume growth** and intense competition. Earnings visibility remains muted for the near term. 📊 *STOCKS:* ABBOTINDIA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #downgrade
Abbott India rating and price target slashed by broker
*Abbott India rating and price target slashed by broker.* Weak growth outlook prompted a double downgrade from a broker, cutting share price expectations. The move reflects concerns over **slowing sales** and **margin pressures** in key segments. This could weigh on near-term investor sentiment. 📊 *STOCKS:* ABBOTINDIA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #broker-downgrade
Abbott India target, rating cut on weak growth
*Abbott India target, rating cut on weak growth* — Brokerage slashed Abbott India's stock price target and rating due to weak growth outlook. Revenue and earnings growth are expected to remain subdued. 📊 *STOCKS:* ABBOTINDIA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #BrokerDowngrade
JPMorgan cuts Abbott India target price; pharma stock downgrade
*JPMorgan cuts Abbott India target price in bearish call on pharma stock.* The downgrade reflects concerns over valuation and growth prospects for the pharmaceutical company. This broker call may trigger selling pressure among retail and institutional investors holding the stock. Monitor support levels for potential entry opportunities. 📊 *STOCKS:* $ABBOTINDIA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #broker_downgrade
Abbott India downgraded on weak growth outlook by broker
*Abbott India share price target and rating slashed on weak growth outlook.* Broker has issued a **double downgrade** citing concerns over the company's **growth trajectory**. This signals deteriorating sentiment among institutional analysts regarding Abbott India's near-term performance prospects. 📊 *STOCKS:* $ABBOTINDIA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #downgrade
About Abbott India Limited
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.[1] It was established in 1944.[2]
Healthcare · Pharmaceuticals & Biotechnology